CN Patent

CN107530287B — 药物制剂

Assigned to Torrent Pharmaceuticals Ltd · Expires 2020-11-10 · 6y expired

What this patent protects

本发明涉及药物制剂，包含1‑(2‑噻吩‑2’‑基‑2‑氧代‑乙基)‑3‑(甲磺酰基肼羰基)吡啶鎓、其药用盐、盐‑共晶体和共晶体，具体地，1‑(2‑噻吩‑2’‑基‑2‑氧代‑乙基)‑3‑5(甲磺酰基肼羰基)吡啶盐酸盐。所述制剂适合于口服施用，并且还包含渗透性增强剂或适合的碱或它们的混合物。本发明的制剂用于治疗与晚期糖基化终产物有关的疾病。

USPTO Abstract

本发明涉及药物制剂，包含1‑(2‑噻吩‑2’‑基‑2‑氧代‑乙基)‑3‑(甲磺酰基肼羰基)吡啶鎓、其药用盐、盐‑共晶体和共晶体，具体地，1‑(2‑噻吩‑2’‑基‑2‑氧代‑乙基)‑3‑5(甲磺酰基肼羰基)吡啶盐酸盐。所述制剂适合于口服施用，并且还包含渗透性增强剂或适合的碱或它们的混合物。本发明的制剂用于治疗与晚期糖基化终产物有关的疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN107530287B
Jurisdiction
CN
Classification
—
Expires
2020-11-10
Drug substance claim
No
Drug product claim
No
Assignee
Torrent Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.